|
JP4713798B2
(ja)
|
1999-06-29 |
2011-06-29 |
マンカインド コーポレイション |
ペプチドおよびタンパク質の薬学的因子の精製および安定化
|
|
US9006175B2
(en)
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
|
US7084243B2
(en)
*
|
2000-06-16 |
2006-08-01 |
Eli Lilly And Company |
Glucagon-like peptide-1 analogs
|
|
US7186683B2
(en)
|
2000-09-18 |
2007-03-06 |
Sanos Bioscience A/S |
Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
|
|
EP1326630B1
(en)
*
|
2000-09-18 |
2008-05-28 |
Sanos Bioscience A/S |
Use of glp-2 peptides
|
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
|
JP5562510B2
(ja)
*
|
2001-06-28 |
2014-07-30 |
ノヴォ ノルディスク アー／エス |
修飾ｇｌｐ−１の安定な処方剤
|
|
CN1363654A
(zh)
|
2001-07-19 |
2002-08-14 |
上海华谊生物技术有限公司 |
生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
|
|
AU2002322403A1
(en)
*
|
2001-08-23 |
2003-03-10 |
Eli Lilly And Company |
Glucagon-like peptide-1 analogs
|
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
|
HUP0700151A2
(en)
*
|
2001-10-18 |
2007-05-29 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
|
ES2545090T3
(es)
|
2001-12-21 |
2015-09-08 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina y GCSF
|
|
ES2280596T3
(es)
*
|
2001-12-29 |
2007-09-16 |
Novo Nordisk A/S |
Uso combinado de un compuesto de glp-1 y un inhibidor de una aldosa reductasa.
|
|
BR0307727A
(pt)
*
|
2002-02-20 |
2005-01-25 |
Lilly Co Eli |
Fomulação
|
|
PT1494732E
(pt)
|
2002-03-20 |
2008-03-20 |
Mannkind Corp |
Aparelho de inalação
|
|
WO2003103572A2
(en)
*
|
2002-06-04 |
2003-12-18 |
Eli Lilly And Company |
Modified glucagon-like peptide-1 analogs
|
|
US20080260838A1
(en)
*
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
|
US7790681B2
(en)
*
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
|
WO2004067548A2
(en)
*
|
2003-01-31 |
2004-08-12 |
Theratechnologies Inc. |
Chemically modified metabolites of regulatory peptides and methods of producing and using same
|
|
US20060217300A1
(en)
*
|
2003-02-19 |
2006-09-28 |
Biomeasure, Incorporated |
Analogues of glp-1
|
|
ES2383752T3
(es)
|
2003-05-15 |
2012-06-26 |
Trustees Of Tufts College |
Analogos estables de GLP-1
|
|
US8008255B2
(en)
*
|
2003-05-30 |
2011-08-30 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
|
ES2380437T3
(es)
*
|
2003-06-03 |
2012-05-11 |
Novo Nordisk A/S |
Composiciones farmacéuticas de péptido GLP-1 estabilizadas
|
|
WO2004105790A1
(en)
*
|
2003-06-03 |
2004-12-09 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
|
MXPA05013565A
(es)
|
2003-06-12 |
2006-03-09 |
Lilly Co Eli |
Proteinas de fusion analogas al glp-1.
|
|
WO2005049061A2
(en)
|
2003-11-20 |
2005-06-02 |
Novo Nordisk A/S |
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
|
|
ATE498404T1
(de)
|
2003-12-09 |
2011-03-15 |
Novo Nordisk As |
Regulierung der nahrungspräferenz mit glp-1- agonisten
|
|
ES2393335T3
(es)
*
|
2003-12-16 |
2012-12-20 |
Ipsen Pharma |
Análogos de GLP-1
|
|
TWI353250B
(en)
*
|
2003-12-16 |
2011-12-01 |
Ipsen Pharma Sas |
Glp-1 pharmaceutical compositions
|
|
US7538185B2
(en)
|
2004-01-08 |
2009-05-26 |
Theratechnologies Inc. |
Glucagon-like peptide-1 analogs with long duration of action
|
|
SI1740039T1
(sl)
|
2004-04-30 |
2012-10-30 |
Dow Agrosciences Llc |
Novi geni z rezistenco na herbicide
|
|
US20090069226A1
(en)
*
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
|
EP2316446A1
(en)
|
2004-06-11 |
2011-05-04 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using GLP-1 agonists
|
|
AU2005277208B2
(en)
|
2004-08-20 |
2011-11-24 |
Mannkind Corporation |
Catalysis of diketopiperazine synthesis
|
|
PL2322180T3
(pl)
|
2004-08-23 |
2015-10-30 |
Mannkind Corp |
Sole diketopiperazyny do dostarczania leków
|
|
US8710181B2
(en)
*
|
2004-08-31 |
2014-04-29 |
Novo Nordisk A/S |
Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
|
|
US8030273B2
(en)
|
2004-10-07 |
2011-10-04 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
|
JP2008515856A
(ja)
*
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
遅延性ｇｌｐ−１化合物
|
|
ES2458991T3
(es)
|
2004-11-12 |
2014-05-07 |
Novo Nordisk A/S |
Formulaciones estables de péptidos insulinotrópicos
|
|
EP2505207B1
(en)
|
2005-01-14 |
2015-04-22 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
|
US8299025B2
(en)
|
2005-02-03 |
2012-10-30 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
|
WO2006098524A1
(ja)
*
|
2005-03-18 |
2006-09-21 |
Ajinomoto Co., Inc. |
ストレスによる腸疾患の予防・治療剤
|
|
ME02786B
(me)
*
|
2005-05-13 |
2011-10-31 |
Lilly Co Eli |
Glp-1 pegilovana jedinjenja
|
|
KR20080028981A
(ko)
*
|
2005-06-30 |
2008-04-02 |
소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. |
Ｇｌｐ-1 약학 조성물
|
|
ES2555310T3
(es)
|
2005-09-14 |
2015-12-30 |
Mannkind Corporation |
Método de formulación de fármacos basado en el incremento de la afinidad de superficies de micropartículas cristalinas por principios activos
|
|
JP5155869B2
(ja)
|
2005-10-28 |
2013-03-06 |
ダウ アグロサイエンシズ リミテッド ライアビリティー カンパニー |
除草剤抵抗性遺伝子
|
|
CA2913805A1
(en)
|
2005-11-07 |
2007-05-18 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
|
CN100374462C
(zh)
*
|
2005-11-21 |
2008-03-12 |
大连帝恩生物工程有限公司 |
截短胰高血糖素样肽1(sGLP-1)、制法及其应用
|
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
|
ES2779992T3
(es)
|
2005-12-20 |
2020-08-21 |
Univ Duke |
Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
|
|
WO2008063203A2
(en)
*
|
2006-01-27 |
2008-05-29 |
Whitehead Institute For Biomedical Research |
Compositions and methods for efficient gene silencing in plants
|
|
CA2643464C
(en)
|
2006-02-22 |
2018-09-04 |
Mannkind Corporation |
A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
|
|
AU2007240313B2
(en)
|
2006-04-20 |
2012-02-02 |
Amgen Inc. |
GLP-1 compounds
|
|
ES2351527T3
(es)
|
2006-05-30 |
2011-02-07 |
Intarcia Therapeutics, Inc |
Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
|
|
CN101466399B
(zh)
*
|
2006-06-09 |
2015-05-13 |
诺华股份有限公司 |
稳定的胰岛素样生长因子多肽
|
|
WO2008005527A2
(en)
*
|
2006-07-06 |
2008-01-10 |
Amylin Pharmaceuticals, Inc. |
Glucagon-like peptides and uses thereof
|
|
BRPI0714334A2
(pt)
*
|
2006-07-18 |
2013-05-14 |
Centocor Inc |
mimeticorpos de glp-1 humano aperfeiÇoados, composiÇÕes, mÉtodos e usos
|
|
JP5048773B2
(ja)
|
2006-08-09 |
2012-10-17 |
インターシア セラピューティクス，インコーポレイティド |
浸透圧式デリバリーシステム及びピストンアセンブリー
|
|
KR100851560B1
(ko)
*
|
2006-12-27 |
2008-08-11 |
고려대학교 산학협력단 |
새로운 글루카곤 유사 펩타이드-1 (ｇｌｐ-1) 작용제 및 그용도
|
|
RU2477286C2
(ru)
|
2007-01-05 |
2013-03-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
|
|
CN101041693B
(zh)
*
|
2007-02-06 |
2011-08-17 |
珠海联邦制药股份有限公司 |
一种降血糖多肽及其应用
|
|
CA2677932A1
(en)
|
2007-02-15 |
2008-08-21 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
GB2448895A
(en)
*
|
2007-05-01 |
2008-11-05 |
Activotec Spp Ltd |
GLP-1 like compounds and uses thereof
|
|
US8464239B2
(en)
*
|
2007-06-11 |
2013-06-11 |
Red Hat, Inc. |
Real-time installation and/or configuration assistant
|
|
ES2646614T3
(es)
|
2007-08-03 |
2017-12-14 |
Eli Lilly And Company |
Uso de un compuesto de FGF 21 y un compuesto de GLP 1 para el tratamiento de la obesidad
|
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
|
CN101969928B
(zh)
*
|
2007-10-24 |
2014-05-07 |
曼金德公司 |
活性剂的递送
|
|
KR101736502B1
(ko)
*
|
2007-10-24 |
2017-05-16 |
맨카인드 코포레이션 |
Ｇｌｐ-1에 의한 유해 효과의 예방 방법
|
|
EP2217701B9
(en)
|
2007-10-30 |
2015-02-18 |
Indiana University Research and Technology Corporation |
Glucagon antagonists
|
|
MX2010004298A
(es)
|
2007-10-30 |
2010-05-03 |
Univ Indiana Res & Tech Corp |
Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
|
|
WO2009102467A2
(en)
|
2008-02-13 |
2009-08-20 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
JP5421362B2
(ja)
|
2008-06-13 |
2014-02-19 |
マンカインド コーポレイション |
薬物送達用の乾燥粉末吸入器およびシステム
|
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
|
WO2009155257A1
(en)
*
|
2008-06-17 |
2009-12-23 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
|
|
CN103641907A
(zh)
|
2008-06-17 |
2014-03-19 |
印第安纳大学研究及科技有限公司 |
胰高血糖素/glp-1受体共激动剂
|
|
PE20100056A1
(es)
|
2008-06-17 |
2010-01-26 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon como agonistas gip
|
|
DK2300083T3
(da)
|
2008-06-20 |
2013-07-22 |
Mannkind Corp |
Interaktivt apparat og fremgangsmåde til realtids-profilering af inhalationsforsøg
|
|
CA2726894A1
(en)
|
2008-06-27 |
2009-12-30 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
|
TWI614024B
(zh)
|
2008-08-11 |
2018-02-11 |
曼凱公司 |
超快起作用胰島素之用途
|
|
CN101337989B
(zh)
*
|
2008-08-28 |
2012-10-24 |
中国药科大学 |
一类新型胰高血糖素样肽-1(glp-1)类似物及其应用
|
|
CN101367873B
(zh)
*
|
2008-10-08 |
2011-05-04 |
南开大学 |
一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
|
|
WO2010054326A2
(en)
|
2008-11-07 |
2010-05-14 |
The General Hospital Corporation |
C-terminal fragments of glucagon-like peptide-1 (glp-1)
|
|
SG172291A1
(en)
|
2008-12-19 |
2011-07-28 |
Univ Indiana Res & Tech Corp |
Amide based glucagon superfamily peptide prodrugs
|
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
|
EP2676695A3
(en)
|
2009-03-11 |
2017-03-01 |
MannKind Corporation |
Apparatus, system and method for measuring resistance of an inhaler
|
|
KR20180079458A
(ko)
|
2009-06-12 |
2018-07-10 |
맨카인드 코포레이션 |
한정된 비표면적을 갖는 디케토피페라진 마이크로입자
|
|
US9150632B2
(en)
|
2009-06-16 |
2015-10-06 |
Indiana University Research And Technology Corporation |
GIP receptor-active glucagon compounds
|
|
UA104766C2
(ru)
|
2009-07-13 |
2014-03-11 |
Зіленд Фарма А/С |
Ацилированные аналоги глюкагона
|
|
DK3311828T3
(da)
|
2009-08-14 |
2021-06-28 |
Phasebio Pharmaceuticals Inc |
Modificerede vasoaktive tarmpeptider
|
|
NO2462246T3
(ru)
|
2009-09-28 |
2018-02-03 |
|
|
|
CA2778890A1
(en)
*
|
2009-10-30 |
2011-05-05 |
Otsuka Chemical Co., Ltd. |
Glycosylated form of antigenic glp-1 analogue
|
|
US9016147B2
(en)
|
2009-11-03 |
2015-04-28 |
Mannkind Corporation |
Apparatus and method for simulating inhalation efforts
|
|
AU2010323117B2
(en)
|
2009-11-25 |
2015-09-03 |
Capsugel Belgium Nv |
Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion
|
|
WO2011075393A2
(en)
|
2009-12-18 |
2011-06-23 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
BR112012018585A2
(pt)
|
2010-01-27 |
2017-01-10 |
Univ Indiana Res & Tech Corp |
conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade
|
|
US9168288B2
(en)
|
2010-04-09 |
2015-10-27 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
|
|
CA2797095A1
(en)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
|
|
KR20130111923A
(ko)
|
2010-05-13 |
2013-10-11 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
|
|
EP2571897B1
(en)
*
|
2010-05-17 |
2014-11-05 |
Betta Pharmaceuticals Co., Ltd. |
Novel glucagon like peptide analogs, composition, and method of use
|
|
RU2531455C2
(ru)
|
2010-06-21 |
2014-10-20 |
Маннкайнд Корпорейшн |
Системы и способы доставки сухих порошковых лекарств
|
|
WO2011163012A2
(en)
|
2010-06-24 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
|
CA2803646A1
(en)
|
2010-07-02 |
2012-01-05 |
Angiochem Inc. |
Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
|
|
US9040481B2
(en)
|
2010-11-02 |
2015-05-26 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
|
KR20130132931A
(ko)
|
2010-12-22 |
2013-12-05 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
Gip 수용체 활성을 나타내는 글루카곤 유사체들
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
JP6133270B2
(ja)
|
2011-04-01 |
2017-05-24 |
マンカインド コーポレイション |
薬剤カートリッジのためのブリスター包装
|
|
CN102180963B
(zh)
*
|
2011-04-22 |
2014-06-25 |
中国药科大学 |
胰高血糖素样肽-1(glp-1)类似物及其应用
|
|
CN102219850A
(zh)
*
|
2011-05-03 |
2011-10-19 |
上海格尼生物技术有限公司 |
新的长效glp-1化合物
|
|
WO2012170524A1
(en)
|
2011-06-06 |
2012-12-13 |
Phasebio Pharmaceuticals, Inc. |
Use of modified vasoactive intestinal peptides in the treatment of hypertension
|
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
|
AU2012273365A1
(en)
|
2011-06-22 |
2014-01-16 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
PL2723367T3
(pl)
|
2011-06-22 |
2017-10-31 |
Univ Indiana Res & Tech Corp |
Koagoniści receptora glukagonu/GLP-1
|
|
WO2013006692A2
(en)
|
2011-07-06 |
2013-01-10 |
The General Hospital Corporation |
Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
|
|
AR088161A1
(es)
*
|
2011-09-23 |
2014-05-14 |
Novo Nordisk As |
Analogos de glucagon
|
|
IN2014DN03093A
(ru)
|
2011-10-24 |
2015-05-15 |
Mannkind Corp |
|
|
ES2672880T3
(es)
|
2011-11-17 |
2018-06-18 |
Indiana University Research And Technology Corporation |
Péptidos de la superfamilia de glucagón que muestran actividad de receptor de glucocorticoides
|
|
MX2014015558A
(es)
|
2012-06-21 |
2015-03-05 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon que exhiben actividad del receptor gip.
|
|
JP6312262B2
(ja)
|
2012-07-12 |
2018-04-18 |
マンカインド コーポレイション |
乾燥粉末薬物送達システム
|
|
WO2014066856A1
(en)
|
2012-10-26 |
2014-05-01 |
Mannkind Corporation |
Inhalable influenza vaccine compositions and methods
|
|
CN103087177A
(zh)
*
|
2012-11-30 |
2013-05-08 |
中国药科大学 |
一类长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
|
CN103087176A
(zh)
*
|
2012-11-30 |
2013-05-08 |
中国药科大学 |
长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
|
CN103087175A
(zh)
*
|
2012-11-30 |
2013-05-08 |
中国药科大学 |
新型长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
|
CN103087178A
(zh)
*
|
2012-11-30 |
2013-05-08 |
中国药科大学 |
长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
|
CN103087179A
(zh)
*
|
2012-11-30 |
2013-05-08 |
中国药科大学 |
长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
|
JP6523247B2
(ja)
|
2013-03-15 |
2019-05-29 |
マンカインド コーポレイション |
微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法
|
|
BR112015025464A2
(pt)
|
2013-04-18 |
2017-10-10 |
Novo Nordisk As |
coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
|
|
WO2015010092A1
(en)
|
2013-07-18 |
2015-01-22 |
Mannkind Corporation |
Heat-stable dry powder pharmaceutical compositions and methods
|
|
JP2016530930A
(ja)
|
2013-08-05 |
2016-10-06 |
マンカインド コーポレイション |
通気装置及び方法
|
|
CN104262481B
(zh)
*
|
2013-08-09 |
2018-02-09 |
天津药物研究院有限公司 |
一种侧链修饰的长效glp‑1类似物的制备方法及其应用
|
|
CN103405753B
(zh)
*
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
|
WO2015148905A1
(en)
|
2014-03-28 |
2015-10-01 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
|
US11052132B2
(en)
|
2014-05-08 |
2021-07-06 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating cystic fibrosis
|
|
US10570184B2
(en)
|
2014-06-04 |
2020-02-25 |
Novo Nordisk A/S |
GLP-1/glucagon receptor co-agonists for medical use
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
|
TW201625672A
(zh)
*
|
2014-10-24 |
2016-07-16 |
默沙東藥廠 |
升糖素及ｇｌｐ－１受體之共促效劑
|
|
CN114652817A
(zh)
|
2015-02-09 |
2022-06-24 |
费斯生物制药公司 |
用于治疗肌肉疾病和病症的方法和组合物
|
|
KR102650751B1
(ko)
|
2015-06-03 |
2024-03-22 |
인타르시아 세라퓨틱스 인코포레이티드 |
임플란트 배치 및 제거 시스템들
|
|
TWI807580B
(zh)
*
|
2015-12-31 |
2023-07-01 |
南韓商韓美藥品股份有限公司 |
三重升糖素/glp-1/gip 受體促效劑
|
|
EP3458084B1
(en)
|
2016-05-16 |
2020-04-01 |
Intarcia Therapeutics, Inc |
Glucagon-receptor selective polypeptides and methods of use thereof
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
AU2018206539A1
(en)
|
2017-01-03 |
2019-07-18 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
|
MA46990B1
(fr)
|
2017-08-24 |
2024-03-29 |
Novo Nordisk As |
Compositions glp-1 et ses utilisations
|
|
WO2019140021A1
(en)
|
2018-01-12 |
2019-07-18 |
Eli Lilly And Company |
Combination therapy
|
|
JOP20200251A1
(ar)
|
2018-04-05 |
2020-10-04 |
Sun Pharmaceutical Ind Ltd |
نظائر glp-1 جديدة
|
|
TWI705820B
(zh)
|
2018-06-22 |
2020-10-01 |
美商美國禮來大藥廠 |
Gip/glp1促效劑組合物
|
|
WO2020077129A1
(en)
|
2018-10-11 |
2020-04-16 |
Intarcia Therapeutics, Inc. |
Human amylin analog polypeptides and methods of use
|
|
WO2020087305A1
(zh)
*
|
2018-10-30 |
2020-05-07 |
刘建宁 |
具有glp-1受体激动剂活性的glp-1多肽及其用途
|
|
CA3056663C
(en)
|
2019-04-05 |
2022-10-18 |
Jeffrey S. RIESMEYER |
Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
|
|
CN110845601B
(zh)
*
|
2019-10-12 |
2021-01-19 |
广东药科大学 |
不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
|
|
CN113728013B
(zh)
|
2020-01-11 |
2022-06-14 |
北京质肽生物医药科技有限公司 |
Glp-1和fgf21的融合蛋白的缀合物
|
|
IL294521A
(en)
|
2020-02-18 |
2022-09-01 |
Novo Nordisk As |
glp-1 compounds and their uses
|
|
US11981718B2
(en)
*
|
2020-05-27 |
2024-05-14 |
Ampsource Biopharma Shanghai Inc. |
Dual-function protein for lipid and blood glucose regulation
|